PARP抑制剂作为新诊断晚期卵巢癌维持治疗的荟萃分析
该荟萃分析纳入比较PARP抑制剂与安慰剂作为一线维持治疗的随机临床试验,汇总结果显示PARP抑制剂显著改善晚期上皮性卵巢癌的无进展生存期(HR=0.53,95%CI 0.40-0.71;P<0.0001),且获益见于BRCA突变、同源重组缺陷(HRD)及非突变BRCA、非HRD亚组。结论认为无论BRCA突变或HRD状态,PARP抑制剂作为含铂化疗后的维持治疗均有效。
要点
- PARP抑制剂一线维持治疗显著改善晚期上皮性卵巢癌无进展生存期(HR=0.53,95%CI 0.40-0.71;P<0.0001)。
- BRCA突变者HR=0.35(95%CI 0.29-0.42;P<0.00001),HRD者HR=0.43(95%CI 0.32-0.60;P<0.00001)。
- 非突变BRCA者HR=0.72(95%CI 0.63-0.82;P<0.00001),非HRD者HR=0.83(95%CI 0.70-0.99;P=0.04)。
核心结论
- PARP抑制剂作为新诊断晚期卵巢癌含铂化疗后的维持治疗有效,无论BRCA突变或HRD状态。
研究设计与样本
- 荟萃分析,检索PubMed、MEDLINE、EMBASE、Cochrane Library和Web of Science数据库。
- 纳入所有比较PARP抑制剂与安慰剂作为卵巢癌一线维持治疗的随机临床试验(RCT)。
- 由两名评价者提取数据,计算汇总风险比(HR)和风险比(RR)及95%置信区间(CI)。
主要发现
- PARP抑制剂与晚期上皮性卵巢癌无进展生存期(PFS)显著改善相关(HR=0.53,95%CI 0.40-0.71;P<0.0001)。
- BRCA突变女性获益(HR=0.35,95%CI 0.29-0.42;P<0.00001)。
- 同源重组缺陷(HRD)者获益(HR=0.43,95%CI 0.32-0.60;P<0.00001)。
- 非突变BRCA者亦获益(HR=0.72,95%CI 0.63-0.82;P<0.00001)。
- 非HRD者亦获益(HR=0.83,95%CI 0.70-0.99;P=0.04)。
临床怎么用
- PARP抑制剂可作为新诊断晚期卵巢癌患者含铂化疗后的维持治疗,无论BRCA突变或HRD状态。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 70% of patients with advanced ovarian cancer have a relapse after primary therapy. New agents and approaches are urgently needed to avoid or slow down this recurrence. OBJECTIVES: To investigate the efficacy of PARP inhibitors (PARPis) as maintenance treatment in patients with newly diagnosed advanced ovarian cancer. SEARCH STRATEGY: PubMed, MEDLINE, EMBASE, Cochrane Library and Web of Science databases. SELECTION CRITERIA: All randomised clinical trials (RCTs) that compared PARPis with placebo as first-line maintenance therapy in ovarian cancer. DATA COLLECTION AND ANALYSIS: Two reviewers extracted data. Pooled hazard ratio (HR) and risk ratio (RR) with 95% confidence interval (CI) were calculated. MAIN RESULTS: PARPis were associated with significant improvement of progression-free survival (PFS) in advanced epithelial ovarian cancer (AeOC) (HR = 0.53, 95% CI 0.40-0.71; P < 0.0001). The benefit was not only in women with BRCA mutations (HR = 0.35, 95% CI 0.29-0.42; P < 0.00001) and homologous recombination deficiency (HRD) (HR = 0.43, 95% CI 0.32-0.60; P < 0.00001), but also in those with nonmutated BRCA (HR = 0.72, 95% CI 0.63-0.82; P < 0.00001) and even non-HRD (HR = 0.83, 95% CI 0.70-0.99; P = 0.04). CONCLUSIONS: PARP inhibitors are effective as maintenance therapy among patients with newly diagnosed advanced ovarian cancer after platinum-based chemotherapy, regardless of BRCA mutation or HRD status. TWEETABLE ABSTRACT: PARPis provide a significant PFS benefit as first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.
引用
- Lin Q, Liu W, Xu S, et al. PARP inhibitors as maintenance therapy in newly diagnosed advanced ovarian cancer: a meta-analysis. BJOG. 2020. PMID: 32654312. doi:10.1111/1471-0528.16411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。